| 1228013-30-6 Basic information More.. |
Product Name: | CC-223 | Synonyms: | CC-223;7-[6-(2-Hydroxypropan-2-yl)pyridin-3-yl]-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one;Pyrazino[2,3-b]pyrazin-2(1H)-one, 3,4-dihydro-7-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-(trans-4-methoxycyclohexyl)-;Onatasertib;7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one;CS-2163;CS-2039;CC223;CC 223 | CAS: | 1228013-30-6 | MF: | C21H27N5O3 | MW: | 397.47 | EINECS: | | Mol File: | 1228013-30-6.mol | |
Use
CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems. After tumor-bearing mice was treated with CC-223 for a single oral dose. It exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts. The observed antitumor activity of CC-223 is likely to be mediated through inhibition of both mTORC1 and mTORC2. CC-223 is currently in phase I clinical trials for its treatment of advanced solid and hematologic cancers.
|
1228013-30-6
Recommend Suppliers |
|